Back to results
US 11,693,007 B2Granted
Assay for detection of early stage pancreatic cancer
AssigneeBoard of Regents, The University of Texas System
InventorsAnn McNeill Killary, Steven T. Lott, Nanyue Chen, Seetharaman Balasenthil
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of detecting pancreatic cancer, particularly early stage pancreatic cancer, comprising measuring the expression of the biomarker panel TNC-FN III-C, TFPI, and CA19-9. The expression may be determined by an ELISA, such as a multiplex ELISA. Further provided herein are methods of treating subjects identified to have pancreatic cancer.
Claims15
A method for measuring the expression of the antigens TNC-FN III-C, TFPI, and CA19-9 comprising:
- (a) contacting a plurality of antigens in a sample with an anti-TNC-FN III-C antibody, an anti-TFPI antibody, and an anti-CA19-9 antibody to form antigen-antibody complexes;
- and
- (b) detecting the antigen-antibody complexes using detectable moieties that distinctly bind each of the antibodies, thereby measuring the expression of the antigens TNC-FN III-C, TFPI, and CA19-9, wherein an increased expression of the TNC-FN III-C, TFPI, and CA19-9 antigens as compared to a control indicates the presence of pancreatic cancer;
- and
- (c) administering one or more anti-cancer therapies to a subject with increased expression of the TNC-FN III-C TFPI, and CA19-9 antigens as compared to a control sample.
2 more elements
Dependencies are inferred from the claim text.